Compare GSK plc (GSK) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Lam Research Corporation — how do they compare? GSK plc trades at $52.73 (market cap $101.34B), while Lam Research Corporation trades at $325.61 (market cap $419.48B). The key difference: Lam Research Corporation is far larger — about 4.1× GSK plc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | LRCX | |
|---|---|---|
Market Cap | $101.34B | $419.48B |
Sector | Health | Technology |
52-Week High | $61.18 | $433.33 |
52-Week Low | $36.20 | $94.84 |
Enterprise Value | $121.95B | $418.46B |
Dividend Yield | 3.49% | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Lam Research (LRCX) trades at $346.10, up 4.9% in the last session, reflecting strong momentum in semiconductor equipment stocks. The stock exhibits bullish technical signals with support at $340 and resistance at $350. Fundamentally, the company reported revenue of $18.44B and net income of $5.36B in 2025, with a robust net margin of 30.94%. Recent quarterly earnings consistently beat expectations, and analyst consensus remains overwhelmingly positive with a $393 price target. The company benefits from AI-driven demand for advanced chip fabrication equipment.
The outlook for LRCX is positive, driven by secular growth in AI and high-performance computing, which fuels demand for its wafer fabrication equipment. Investment opportunities include continued market share gains and margin expansion. Key risks include cyclical semiconductor capital expenditure downturns, intense competition from peers like Applied Materials, and a premium valuation (P/E of 63.41) that leaves the stock vulnerable to multiple compression if growth expectations moderate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
